Next Article in Journal
Pre-Clinical Intravenous Serum Pharmacokinetics of Albumin Binding and Non-Half-Life Extended Nanobodies®
Next Article in Special Issue
Targeting of Tumor Necrosis Factor Alpha Receptors as a Therapeutic Strategy for Neurodegenerative Disorders
Previous Article in Journal
Purpose-Oriented Antibody Libraries Incorporating Tailored CDR3 Sequences
Previous Article in Special Issue
Targeting sTNF/TNFR1 Signaling as a New Therapeutic Strategy
 
 
Article

Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics

1
Institute of Medical Biology, University of Szeged, 6720, Szeged, Hungary
2
Department of Pathophysiology and Allergy Research, Center for Pathophysiology, Infectiology and Immunology, Medical University of Vienna, 1090, Vienna, Austria
*
Author to whom correspondence should be addressed.
Academic Editor: Olaf Maier
Antibodies 2015, 4(2), 123-140; https://doi.org/10.3390/antib4020123
Received: 17 February 2015 / Revised: 11 May 2015 / Accepted: 29 May 2015 / Published: 9 June 2015
(This article belongs to the Special Issue TNF in the Regulation of Immune Cells)
Anti-tumor necrosis factor (TNF) monoclonal antibodies and TNF receptor ectodomain fusion protein are in clinical use to neutralize circulating TNF and ameliorate symptoms of many autoimmune diseases and pathological conditions with chronic inflammation. In this paper we present data to prove that reverse signaling, elicited by agonist molecules interacting with the membrane-bound TNF of myeloid cells, significantly contributes to the therapeutic effect of these anti-TNF medicines. Interaction of agonist monoclonals with cell surface TNF significantly attenuates the expression of pro-inflammatory cytokines and induces changes in the production of extracellular and intracellular signaling molecules. This phenomenon is not dependent on the Fc portion of antibodies as Fab constructs are as efficient as full antibody molecules. View Full-Text
Keywords: autoimmune; monoclonal antibodies; inflammation; macrophage; reverse signal; tumor necrosis factor (TNF); TNF receptor autoimmune; monoclonal antibodies; inflammation; macrophage; reverse signal; tumor necrosis factor (TNF); TNF receptor
Show Figures

Figure 1

MDPI and ACS Style

Sipos, O.; Török, A.; Kalic, T.; Duda, E.; Filkor, K. Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics. Antibodies 2015, 4, 123-140. https://doi.org/10.3390/antib4020123

AMA Style

Sipos O, Török A, Kalic T, Duda E, Filkor K. Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics. Antibodies. 2015; 4(2):123-140. https://doi.org/10.3390/antib4020123

Chicago/Turabian Style

Sipos, Orsolya, Annamária Török, Tanja Kalic, Ernő Duda, and Kata Filkor. 2015. "Reverse Signaling Contributes to Control of Chronic Inflammation by Anti-TNF Therapeutics" Antibodies 4, no. 2: 123-140. https://doi.org/10.3390/antib4020123

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Back to TopTop